Clinical Trial: A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07294625) titled 'A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma' on Dec. 08.

Brief Summary: This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.

Study Start Date: Dec. 10

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma

Intervention: BIOLOGICAL: LVIVO-TaVec200 product

Prior to infusion of the LVIVO-TaVec200 product, subjects will receive bridging therapy if needed.

Recruitment Status: RECRUITING

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Publish...